295 related articles for article (PubMed ID: 11103058)
41. Arsenic trioxide as first-line treatment for acute promyelocytic leukemia.
Leu L; Mohassel L
Am J Health Syst Pharm; 2009 Nov; 66(21):1913-8. PubMed ID: 19850784
[TBL] [Abstract][Full Text] [Related]
42. Prolonged oral arsenic trioxide therapy and nephrolithiasis [corrected].
Au WY; Tam S; Fong BM; Ho KL; Tam PC; Kwong YL
Leuk Lymphoma; 2007 Nov; 48(11):2233-4. PubMed ID: 17926176
[No Abstract] [Full Text] [Related]
43. Cardiac toxicity of arsenic trioxide.
Barbey JT
Blood; 2001 Sep; 98(5):1632; author reply 1633-4. PubMed ID: 11547771
[No Abstract] [Full Text] [Related]
44. Thyroid arsenic content and papillary thyroid carcinoma arising 10 years after oral arsenic trioxide therapy for refractory acute promyelocytic leukemia.
Au WY; Lang BH; Fong BM; Mao KJ; Tam S
Leuk Lymphoma; 2014 May; 55(5):1184-5. PubMed ID: 23964647
[No Abstract] [Full Text] [Related]
45. Entry of elemental arsenic into the central nervous system in patients with acute promyelocytic leukemia during arsenic trioxide treatment.
Au WY; Tam S; Kwong YL
Leuk Res; 2008 Feb; 32(2):357-8. PubMed ID: 17662385
[No Abstract] [Full Text] [Related]
46. [Arsenic trioxide: "a successful poison" in patients with acute promyelocytic leukemia].
Lengfelder E; Schultheis B; Büchner T; Hehlmann R
Dtsch Med Wochenschr; 2007 Feb; 132(7):330-6. PubMed ID: 17286223
[No Abstract] [Full Text] [Related]
47. Does arsenic trioxide impact fertility?
Stein EM; Tallman MS
Leuk Lymphoma; 2012 Nov; 53(11):2099-100. PubMed ID: 22524541
[No Abstract] [Full Text] [Related]
48. [Study on cardiac toxicity in acute promyelocyte leukemia treatment of arsenic trioxide intravenous infusion in general dose].
Zhou J; Meng R; Wang W; Lü CF; Yang BF
Zhonghua Nei Ke Za Zhi; 2003 Nov; 42(11):785-8. PubMed ID: 14636467
[TBL] [Abstract][Full Text] [Related]
49. Arsenic trioxide and olanzapine co-administration: case analysis.
Kaufman KR; Chhabra S; Levitt M; Sood R
J Oncol Pharm Pract; 2011 Sep; 17(3):260-4. PubMed ID: 20015926
[TBL] [Abstract][Full Text] [Related]
50. Arsenic trioxide in the treatment of relapsed and refractory acute promyelocytic leukemia.
Asou N
Intern Med; 2005 Aug; 44(8):775-6. PubMed ID: 16157968
[No Abstract] [Full Text] [Related]
51. Retinoic acid and arsenic trioxide for acute promyelocytic leukemia.
Lo-Coco F; Avvisati G; Vignetti M; Thiede C; Orlando SM; Iacobelli S; Ferrara F; Fazi P; Cicconi L; Di Bona E; Specchia G; Sica S; Divona M; Levis A; Fiedler W; Cerqui E; Breccia M; Fioritoni G; Salih HR; Cazzola M; Melillo L; Carella AM; Brandts CH; Morra E; von Lilienfeld-Toal M; Hertenstein B; Wattad M; Lübbert M; Hänel M; Schmitz N; Link H; Kropp MG; Rambaldi A; La Nasa G; Luppi M; Ciceri F; Finizio O; Venditti A; Fabbiano F; Döhner K; Sauer M; Ganser A; Amadori S; Mandelli F; Döhner H; Ehninger G; Schlenk RF; Platzbecker U; ; ;
N Engl J Med; 2013 Jul; 369(2):111-21. PubMed ID: 23841729
[TBL] [Abstract][Full Text] [Related]
52. Acute intestinal pseudo-obstruction after induction treatment of relapsed acute promyelocytic leukemia with arsenic trioxide.
Park JA; Yun JH; Kang HJ; Shin HY; Ahn HS
Pediatr Blood Cancer; 2008 Apr; 50(4):872-4. PubMed ID: 17635008
[TBL] [Abstract][Full Text] [Related]
53. Effects of oral arsenic trioxide therapy on QT intervals in patients with acute promyelocytic leukemia: implications for long-term cardiac safety.
Siu CW; Au WY; Yung C; Kumana CR; Lau CP; Kwong YL; Tse HF
Blood; 2006 Jul; 108(1):103-6. PubMed ID: 16514059
[TBL] [Abstract][Full Text] [Related]
54. Dose-adjusted arsenic trioxide for acute promyelocytic leukaemia in chronic renal failure.
Firkin F; Roncolato F; Ho WK
Eur J Haematol; 2015 Oct; 95(4):331-5. PubMed ID: 25600167
[TBL] [Abstract][Full Text] [Related]
55. [Successful treatment of relapsed and refractory acute promyelocytic leukemia with arsenic trioxide (As2O3)].
Tanaka Y; Komatsu H; Ishii K; Nakamura F; Hayashi T; Sawada H; Ono Y; Imanaka T
Rinsho Ketsueki; 2000 Apr; 41(4):354-7. PubMed ID: 10846468
[TBL] [Abstract][Full Text] [Related]
56. Leukocytosis and retinoic acid syndrome in patients with acute promyelocytic leukemia treated with arsenic trioxide.
Jin B; Hou KZ; Liu YP; Yu P
Chin Med Sci J; 2006 Sep; 21(3):171-4. PubMed ID: 17086739
[TBL] [Abstract][Full Text] [Related]
57. Prolongation of cardiac repolarization by arsenic trioxide.
Chiang CE; Luk HN; Wang TM; Ding PY
Blood; 2002 Sep; 100(6):2249-52. PubMed ID: 12200393
[TBL] [Abstract][Full Text] [Related]
58. Studies on curative efficacy of monoterpene eugenol on anti- leukemic drug arsenic trioxide induced cardiotoxicity.
Binu P; Priya N; Abhilash S; Vineetha RC; Nair RH
Biomed Pharmacother; 2017 Jul; 91():559-566. PubMed ID: 28494415
[TBL] [Abstract][Full Text] [Related]
59. Arsenic methylation metabolism and liver injury of acute promyelocytic leukemia patients undergoing arsenic trioxide treatment.
Wang H; Xi S; Liu Z; Yang Y; Zheng Q; Wang F; Xu Y; Wang Y; Zheng Y; Sun G
Environ Toxicol; 2013 May; 28(5):267-75. PubMed ID: 23589229
[TBL] [Abstract][Full Text] [Related]
60. Recurrent acute myopericarditis without effusion during ATRA induction and ATO salvage of APL: a variant form of the differentiation syndrome?
Vassilakopoulos TP; Asimakopoulos JV; Plata E; Kelepesis G; Petevi K; Koutsi C; Papageorgiou L; Tsaftaridis P; Angelopoulou MK; Konstantopoulos K; Meletis J
Leuk Lymphoma; 2017 Jul; 58(7):1743-1746. PubMed ID: 27919176
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]